Sign Up Today and Learn More About GenePartner Stock
Invest in or calculate the value of your shares in GenePartner or other pre-IPO companies through EquityZen's platform.
About GenePartner Stock
Founded
2008
Industries
Software, Artificial Intelligence, Data and Analytics
Switzerland-based GenePartner says they can use a $99 DNA test (compare to $399 for 23andMe) to help you find your perfect match, statistically speaking. They've analyzed "hundreds of couples" and have determined the genetic patterns found in successful relationships. Based on their algorithm and your DNA, they'll determine the probability for a satisfying and long-lasting relationship between two people. A brush for collecting your DNA sample from your saliva — called a buccal swab kit — will be sent to your address. Following the simple instructions included with the kit you will gently collect the DNA from the inside of your cheek. Use the addressed envelope supplied for returning the brushes. GenePartner is looking to partner with dating sites and have those services encourage users to see if they're a DNA match.
GenePartner Press Mentions
Stay in the know about the latest news on GenePartner
You, me, and “science” makes three: the state of online dating
arstechnica • Sep 29, 2015
Looking for Love In All the Right Alleles
wired • Sep 29, 2015
Looking for Love In All the Right Alleles | WIRED
wired • May 21, 2015
How Do I Look in These Genes? The Science of DNA Dating
gizmodo • May 12, 2015
You, me, and "science" makes three: the state of online dating
arstechnica • May 12, 2015
GenePartner Management
Leadership team at GenePartner
CEO
Joelle Apter
Managing Director
Tamara Brown
Join now and verify your accreditation status to gain access to:
- GenePartner Current Valuation
- GenePartner Stock Price
- GenePartner Management
- Available deals in GenePartner and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- GenePartner Cap Table and Funding History by Share Class and Liquidity Preferences
- GenePartner Revenue and Financials
- GenePartner Highlights
- GenePartner Business Model
- GenePartner Risk Factors
- GenePartner Research Report from SACRA Research
Trading GenePartner Stock
How to invest in GenePartner stock?
Accredited investors can buy pre-IPO stock in companies like GenePartner through EquityZen funds. These investments are made available by existing GenePartner shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell GenePartner stock?
Shareholders can sell their GenePartner stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
